ng28ÄϹ¬ºÍ²³½¡Ðû²¼£¬ng28ÄϹ¬ÒÑÏòÖйú¹ú¼ÒÒ©Æ·¼à¶½ÖÎÀí¾ÖÌá½»ÂØ¿¨Ä¹£¨lecanemab£¬¿ª·¢´úºÅ: BAN2401£©ÉÏÊÐÉêÇ룬ÂØ¿¨Ä¹ÊÇ°¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕÏ°£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆΪÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) ÔÏËά¿¹Ìå¡£
ÂØ¿¨Ä¹µÄÉêÇëÀà±ðΪһÀàÐÂÒ©£¨Î´ÔÚÖйú»òÈκÎÆäËû¹ú¼ÒÅú×¼µÄÁ¢ÒìÒ©£©¡£
ÂØ¿¨Ä¹Ñ¡ÔñÐԵؽáºÏ²¢Ïû³ý¿ÉÈÜÐÔ¡¢¶¾ÐÔµí·ÛÑù¦Â£¨A¦Â£©¾Û¼¯Ì壨ÔÏËά£©£¬ÕâЩ¾Û¼¯Ìå±»ÈÏΪµ¼ÖÂADµÄÉñ¾±äÐÔÀú³Ì¡£Òò´Ë£¬ÂØ¿¨Ä¹½«»á¶Ô¼²²¡²¡Àíѧ±¬·¢Ó°Ï죬²¢¼õ»º¼²²¡µÄ½øÕ¹¡£Clarity ADÑо¿µÄÂØ¿¨Ä¹µÖ´ïÁËÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦µÄ´ÎÒªÖյ㣬½á¹û¾ßÓÐÏÔÖøͳ¼ÆѧÒâÒå¡£2022Äê11Ô£¬Clarity ADÑо¿µÄ½á¹ûÔÚ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©¼¯»áÉÏÐû²¼£¬²¢Í¬Ê±Ðû²¼ÔÚÊÀ½ç×îÖøÃûµÄͬÐÐÆÀÉóҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£
ÔÚÃÀ¹ú£¬ÂØ¿¨Ä¹»®·ÖÓÚ2021Äê6ÔºÍ12Ô±»ÃÀ¹úʳƷºÍÒ©ÎïÖÎÀí¾Ö£¨FDA£©ÊÚÓèÍ»ÆÆÐÔÁÆ·¨ºÍ¿ìËÙͨµÀµÄ³Æºô¡£2022Äê7Ô£¬FDAÔÚ¿ìËÙͨµÀÈ϶¨Ï½ÓÊÜÁËng28ÄϹ¬µÄÂØ¿¨Ä¹µÄÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루BLA£©£¬²¢ÊÚÓèÆäÓÅÏÈÉó²éȨ¡£´¦·½Ò©Óû§Óöȷ¨°¸µÄÐж¯£¨PDUFA£©ÈÕÆÚ¶¨ÓÚ2023Äê1ÔÂ6ÈÕ¡£ng28ÄϹ¬µÄÄ¿±êÊÇÔÚ2022²ÆÎñÄê¶È½áÊøÇ°£¬ÔÚÃÀ¹úÉêÇëÍêÈ«Åú×¼£¬ÔÚÈÕ±¾ºÍÅ·ÖÞÉêÇëÉÏÊÐÐí¿É¡£
ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹ㣬ÆäÖÐng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£
Eisai Co., Ltd.
Public Relations Department
TEL: +81-(0)3-3817-5120
INVESTOR CONTACT:
Investor Relations Department
TEL: +81-(0)3-3817-5122
Biogen Inc.
Natacha Gassenbach
+ 1-857-777-6573
public.affairs@biogen.com
Mike Hencke
+ 1-781-464-2442
IR@biogen.com